Shots:
- Neurogen Biomarking partnered with Linus Health to form a unified platform by incorporating the latter’s digital cognitive assessments with the Neurogen Biomarking ecosystem, commercially available in Q1’25
- The new platform will integrate early detection & care for patients with MCI or dementia related to AD with Linus Health’s scientifically validated assessments to identify high-risk cases & check their eligibility for easy-to-use at-home blood biomarker test to measure p-tau 217 levels
- In addition, the platform will offer personalized healthcare plans & organized telehealth appointments with board-certified neurologists
Ref: Businesswire | Image: Neurogen Biomarking & Linus Health
Related News:- The US FDA grants 510(k) Clearance to Werfen’s Aptiva Antiphospholipid Syndrome (APS) Reagents
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
